nivolumab
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
EMA Accepts Application for Subcutaneous Opdivo Across Multiple Indications
The application was based on results from a Phase III trial showing subcutaneous Opdivo was noninferior to intravenous use.
Tumor Forecasting Using Mechanistic Rules of Biology May Improve Predictive Models, Study Suggests
Premium
Incorporating mathematical biological rules into spatial models of tumor response can yield insights into tumor progression and response, early study shows.
Apr 27, 2023
Feb 2, 2023